Supernus Pharmaceuticals, Inc. (SUPN) is a specialty pharmaceutical company that focuses on the development and commercialization of products for treating central nervous system diseases. Based in Rockville, Maryland, Supernus Pharmaceuticals, Inc. is known for its efforts to address unmet medical needs in neurology, psychiatry, and chronic pain through advanced technology and research.
The company was incorporated in 2005 in Delaware and went public in 2012. Since then, it has grown consistently with numerous product offerings under its name. Its significant product portfolio includes extended-release treatments for epilepsy and attention deficit hyperactivity disorder (ADHD). Some noteworthy products are Trokendi XR and Oxtellar XR, two extended-release formulations for epilepsy treatment, as well as Qelbree, for treating ADHD.
Supernus Pharmaceuticals is committed to maintaining its position as a leader in CNS diseases by bridging the gap between medical needs and available treatments. It does so primarily through its robust drug pipeline, including several product candidates under various stages of development for conditions such as Parkinson's disease and depression.
The company's long-term success is underpinned by its dedication to innovation, unyielding focus on patient needs, and deep commitment to scientific rigor. Supernus' experienced leadership team, comprised of individuals with significant industry experience, ensures its strategic decisions serve patients effectively, while contributing to the company's overall growth.
Supernus Pharmaceuticals, Inc. is distinguished by its R&D capabilities as it invests significantly in research to explore innovative solutions for central nervous system conditions. Its state-of-the-art laboratories and R&D centers facilitate breakthrough innovations.
Over the years, Supernus' groundbreaking solutions have earned it several accolades and patents, reinforcing its commitment to improving patients' lives through advanced medical solutions. The company's strong track record and robust pipeline of transformative medicines position it to continue making a significant impact in addressing the challenges of CNS diseases.
Supernus Pharmaceuticals Inc has also established business relations with several key industry players, not only in North American markets but broadly around the world. Moreover, its commitment to corporate responsibility, including upholding ethical standards in all its operations, practices, and interactions, stands as a testament to its dedication to societal wellbeing.
By delivering a full range of treatments catering to diverse CNS conditions, Supernus Pharmaceuticals, Inc. has created a niche for itself in specialty pharmaceuticals. As the company continues to grow, it will remain dedicated to enhancing patient care and quality of life through scientific innovation.